- Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Read more about Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China

Read more about Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China

Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Read more about Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors

Read more about Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors

Donald J. Santel

Member of the Compensation Committee

Donald J. Santel

Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants

Read more about Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants

Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray

Read more about Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray

Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

Read more about Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

Information Requests

© 2021 Oyster Point Pharma, Inc. Oyster Point^™ and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.